Unusual case of propofol-related infusion syndrome complicating severe COVID-19 ARDS.
Acute renal failure
Adult intensive care
COVID-19
Drugs and medicines
Unwanted effects / adverse reactions
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
10
2
2023
Statut:
epublish
Résumé
An elderly man presenting with shortness of breath and hypoxaemia was admitted with acute hypoxic respiratory failure secondary to COVID-19 pneumonia. Due to worsening hypoxaemia, he was transferred to the intensive care unit and required mechanical ventilation. Propofol was infused at 1.5-4 mg/kg/hour. Within 48 hours of initiation, we noticed worsening metabolic acidosis, acute kidney injury, hyperkalaemia, hyperphosphataemia, hypertriglyceridaemia, elevated creatine kinase and elevated myoglobin levels. Suspecting propofol-related infusion syndrome (PRIS), we discontinued his propofol infusion immediately and initiated supportive measures. In 48 hours, there was a significant improvement in metabolic acidosis, hypertriglyceridaemia, rhabdomyolysis and renal function. The propofol infusion rate and cumulative propofol dosage (under 140 mg/kg) were well below levels associated with PRIS. COVID-19's pathogenesis, still under investigation, may have contributed to this presentation. It is imperative for clinicians to maintain a high degree of suspicion once propofol is initiated, regardless of the cumulative dose or rate of infusion.
Identifiants
pubmed: 36750301
pii: 16/2/e249456
doi: 10.1136/bcr-2022-249456
pmc: PMC9906275
pii:
doi:
Substances chimiques
Propofol
YI7VU623SF
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Pharmacotherapy. 2000 Sep;20(9):1120-2
pubmed: 10999506
Lancet. 2001 Jan 13;357(9250):117-8
pubmed: 11197401
J Intensive Care Med. 2011 Mar-Apr;26(2):59-72
pubmed: 21464061
N Engl J Med. 1995 Jul 20;333(3):147-54
pubmed: 7791816
Crit Care Explor. 2020 Dec 16;2(12):e0303
pubmed: 33354676
Clin Pharmacokinet. 2018 Dec;57(12):1539-1558
pubmed: 30019172
Intensive Care Med. 2003 Sep;29(9):1417-25
pubmed: 12904852
Br J Anaesth. 2020 Nov;125(5):e441-e442
pubmed: 32912604
N Engl J Med. 2014 Jan 30;370(5):444-54
pubmed: 24476433
Am J Emerg Med. 2022 Apr;54:309-311
pubmed: 34020844
Br J Anaesth. 2019 Apr;122(4):448-459
pubmed: 30857601
Crit Care Med. 2009 Dec;37(12):3024-30
pubmed: 19661801
Anesth Analg. 2006 Oct;103(4):1050
pubmed: 17000843
Anaesthesia. 2007 Jul;62(7):690-701
pubmed: 17567345
Crit Care Res Pract. 2015;2015:260385
pubmed: 25954513
Eur J Anaesthesiol. 2006 Dec;23(12):990-8
pubmed: 16938158
Ann Pharmacother. 2022 Jan;56(1):5-15
pubmed: 33985368
Crit Care. 2009;13(5):R169
pubmed: 19874582
J Med Virol. 2020 Oct;92(10):1791-1792
pubmed: 32314799